secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001104659-26-036821
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics raises $30M, confirms partial response for APR-1051 in Phase 1 trial
--------------------------------------------------------------------------------

- Raised ~$30M via pre-funded warrants ($0.808) and common warrants ($0.683) expiring Dec. 31, 2029; led by Soleus Capital.
- Confirmed partial response in PPP2R1A-mutated endometrial cancer patient at 220 mg; target lesion reduction 59.5%, CA-125 drop from 362 to 40.2 U/mL.
- Two partial responses in endometrial cancer with PPP2R1A mutations; five stable diseases including HPV+ HNSCC, colorectal, and endometrial cancers.
- Cash runway extended into Q1 2028; dose escalation to 300 mg QD planned in Q2 2026.
- Oversubscribed offering; Oppenheimer & Co. and Maxim Group acted as placement agents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000110465926036821/0001104659-26-036821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000110465926036821/tm2610566d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-036821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer